Why the study?
Evidence was needed to determine whether FFR-guided complete revascularisation by PCI is superior to usual care in patients with non-STEMI and multivessel disease.
Does FFR-guided complete revascularisation by PCI reduce MACCE compared to usual care in patients with non-STEMI and multivessel disease?
Does FFR-guided complete revascularisation by PCI reduce MACCE compared to usual care in patients with non-STEMI and multivessel disease?
The SLIM trial is designed to determine whether FFR-guided complete revascularization during the index procedure improves clinical outcomes compared to usual care in non-STEMI patients with multivessel disease.
Answers are grounded in this paper and cite their sources.
May support index FFR-guided complete PCI in non-STEMI with MVD; Level 3 RCT extends STEMI data but leaves practice change open.
AIMS: To compare ischaemia-driven complete coronary revascularisation by percutaneous coronary intervention (PCI) with usual care in patients with non-ST-elevation myocardial infarction (non-STEMI) and multivessel disease (MVD). METHODS: The South Limburg Myocardial Infarction (SLIM) trial (NCT03562572) is an investigator-initiated, prospective, multicentre, randomised controlled trial that compares fractional flow reserve (FFR)-guided complete revascularisation during the index procedure with usual care in non-STEMI patients with MVD. A total of 414 patients will be randomised in a 1:1 fashion. The primary endpoint is the composite of all-cause mortality, non-fatal myocardial infarction, and any revascularisation and stroke (MACCE) at 12 months. The secondary endpoints are: MACCE at 24 and 36 months, and the composite of cardiac death, myocardial infarction, any revascularisation, stroke, major bleeding and left ventricular ejection fraction below 45% at 12, 24 and 36 months. Furthermore, quality of life will be assessed by the Patient Health Questionnaire (PHQ-9) and the Short Form (36) Health Survey (SF-36) at 1 and 12 months of follow-up. CONCLUSION: The SLIM trial aims to provide evidence whether FFR-guided complete revascularisation by PCI is superior to usual care with respect to clinical outcomes (major adverse cardiovascular events) in non-STEMI patients with MVD.
No takes yet. Share an insight, caveat, or question.
Pustjens et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: